DLL3 Knockout SHP-77 Cell Line

DLL3 Knockout SHP-77 Cell line is a human small cell lung cancer (SCLC) cell line, in which DLL3 (Delta-like canonical Notch ligand 3) is not expressed due to CRISPR/Cas9 genome editing. This cell line was validated by flow cytometry. Small cell lung cancer (SCLC), an aggressive form of cancer, accounts for about 15% of lung cancer diagnoses in the United States. SCLC often goes undetected until it has spread, making treatment challenging. The five-year survival rate is less than 10%. There is still a critical need to develop targeted therapeutics for SCLC, particularly given the high rate of relapses after treatment with current therapies. DLL3 (Delta-like canonical Notch ligand 3) is an inhibitory Notch ligand expressed during embryonic development but rarely in healthy adult cells. However, DLL3 is expressed on the surface of several types of cancer cells, including over 80% of SCLC tumors, making it a potential target for cancer-specific therapeutics. In 2024, Imdelltra(TM) (tarlatamab-dlle), a bispecific T-cell engager (BiTE) targeting CD3 and DLL3, became the first FDA-approved T cell engager therapy for extensive-stage SCLC. Further studies on DLL3-targeted therapies will be important for identifying new treatment strategies for small cell lung cancer.